Cosmos Health CEO acquires $63,000 in stock at $0.36 per share

Cosmos Health Inc. (NASDAQ:COSM), a healthcare company with a market capitalization of $9.79 million, recently reported that its Chief Executive Officer, Grigorios Siokas, acquired 175,000 shares of the company’s common stock. The shares were purchased at a price of $0.36 each, totaling $63,000. This transaction was part of a debt exchange agreement between Mr. Siokas and the company, converting a debt owed to him into equity. Following this transaction, Siokas holds a total of 4,945,214 shares directly. According to InvestingPro analysis, the company currently trades below its Fair Value, with total debt of $11.82 million. InvestingPro subscribers have access to 13 additional key insights about Cosmos Health’s financial health and valuation metrics.

In other recent news, Cosmos Health Inc. has announced a significant contract manufacturing agreement with Pharmex S.A. to produce 1.5 million units of the antiseptic drug AMBITASOL 1L over five years. This development is part of Cosmos Health’s broader strategy to enhance revenue through its subsidiary, Cana Laboratories, which has recently upgraded its manufacturing facilities in Athens. Additionally, Cosmos Health has entered the Albanian market with its Sky Premium Life food supplements brand, partnering with Pharma Cell for distribution, securing an initial annual order valued at $300,000.

The company has also postponed its planned securities offering, initially set to be conducted under its Registration Statement on Form S-1, as it prepares to file its Annual Report on Form 10-K. Meanwhile, Cosmos Health is advancing its weight management product, CCX0722, to clinical trials, with a market launch anticipated in the first half of 2026. In the realm of cancer treatment, Cosmos Health has filed two new patent applications targeting glioma and hematologic malignancies, in collaboration with Cloudpharm and the National Hellenic Research Foundation.

These patent filings are supported by preclinical studies and Cosmos Health’s AI-powered Cloudscreen platform, which aids in drug repurposing efforts. The company continues to focus on expanding its global distribution and R&D partnerships to address major health disorders. Investors are advised to consider the risks and uncertainties detailed in Cosmos Health’s filings with the SEC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.